medRxiv preprint doi: https://doi.org/10.1101/2023.01.30.23285174; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Molecular Epidemiology and Diversity of SARS-CoV-2 in Ethiopia, 2020-2022

Abay Sisay[1, 2, ¶,*], Derek Tshiabuila[3, 4,¶] Abraham Tesfaye[1,5], Gerald Mboowa[6], Samuel O. Oyola[7], Sofonias Kifle Tesema[6], Cheryl Baxter[3,4], Darren Martin[3,4], Richard Lessells[3,4], Houriiyah Tegally[3,4], Stephanie van Wyk[3,4], Monika Moir[3,4], Jennifer Giandhari [3,4], Sureshnee Pillay[3,4], Lavanya Singh[3,4], Yajna Ramphal[3,4], Arisha Maharaj[3,4],Yusasha Pillay[3,4], Akhil Maharaj [3,4], Yeshnee Naidoo[3,4], Upasana Ramphal[3,4], Lucious Chabuka[3,4] ,Eduan Wilkinson[3,4], Tulio de Oliveira[3,4,8], Adey Feleke Desta[2] and James E. San[3,4, *]

[1]Department of Medical Laboratory Sciences, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia
[2]Department of Microbial, Cellular, and Molecular Biology, College of Natural and Computational Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
[3]KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
[4]Centre for Epidemic Response and Innovation (CERI), School of Data Science and Computational Thinking, Stellenbosch University, Stellenbosch, South Africa.
[5]Diagnostic Unit, Center for Innovative Drug Development and Therapeutic Trials for Africa, CDT-Africa, Addis Ababa, Ethiopia
[6] Institute of Pathogen Genomics, Africa Center for Disease Control and Prevention (Africa CDC), Addis Ababa, Ethiopia.
[7]International Livestock Research Institute (ILRI), Nairobi, Kenya.
[8]Department of Global Health, University of Washington; Seattle, USA.

*Corresponding author(s): Abay Sisay (abay.sisay@aau.edu.et), San E James (sanemmanueljames@gmail.com)

[¶] These authors contributed equally to this work

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2023.01.30.23285174; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Abstract

Ethiopia is the second most populous country in Africa and the sixth most affected by COVID-19 on the continent. Despite having experienced five infection waves, >499 000 cases, and ~7 500 COVID-19-related deaths as of January 2023, there is still no detailed genomic epidemiological report on the introduction and spread of SARS-CoV-2 in Ethiopia. In this study, we reconstructed and elucidated the COVID-19 epidemic dynamics. Specifically, we investigated the introduction, local transmission, ongoing evolution, and spread of SARS-CoV-2 during the first four infection waves using 353 high-quality near-whole genomes sampled in Ethiopia. Our results show that whereas viral introductions seeded the first wave, subsequent waves were seeded by local transmission. The B.1.480 lineage emerged in the first wave and notably remained in circulation even after the emergence of the Alpha variant. The B.1.480 was out-competed by the Delta variant. Notably, Ethiopia's lack of local sequencing capacity was further limited by sporadic, uneven, and insufficient sampling that limited the incorporation of genomic epidemiology in the epidemic public health response in Ethiopia. These results highlight Ethiopia's role in SARS-CoV-2 dissemination and the urgent need for balanced, near-real-time genomic sequencing.

Keywords: COVID-19, Molecular epidemiology, SARS-CoV-2, Whole Genome Sequence, Ethiopia

medRxiv preprint doi: https://doi.org/10.1101/2023.01.30.23285174; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Introduction

Ethiopia is a landlocked country in Eastern Africa [1, 2]. It is further one of the most populous countries on the continent, and following the global trend, has accordingly endured severe economic and healthcare burdens due to the ongoing COVID-19 pandemic [3,4]. On 13 March 2020, the Federal Ministry of Health in Ethiopia reported its first COVID-19 case in Addis Ababa. By February 2022, Ethiopia had recorded approximately 494,760 confirmed cases and 7,572 deaths [5, 6]. Despite various pandemic mitigation strategies implemented by the government (Table S1), the number of COVID-19 cases continued to rise. Ethiopia currently constitutes one of the most severely affected countries on the African continent. On the 8th of April 2020, the Ethiopian government declared a 5-month national state of emergency to control and contain the growth rate of the local epidemic and support mitigation mechanisms [7,8]. These emergency measures included the closing of schools and other academic institutes, restrictions on large gatherings, and implementation of mask mandates. These restrictions were complemented by encouraging social distancing and hand washing using multimedia campaigns [7, 9, 10]. While genetic diversity is a major driver of epidemic dynamics, until now, no detailed molecular epidemiology and genetic diversity analyses of SARS-CoV-2 have been performed in Ethiopia. To address this problem, we analyzed 353 high-quality near complete SARS-CoV-2 genomes sampled in Ethiopia against a globally representative set to characterize the introduction, transmission, and spread of SARS-CoV-2 in Ethiopia.

Materials and Methods

Ethical Consideration

This study was reviewed and got approved by Addis Ababa University, College of Health Science Institutional Review Board (IRB) (IRB # 029/20/Lab), IRB of the Department of Medical Laboratory Sciences, Addis Ababa University (reference #-MLS/174/21), IRB office of Addis Ababa City Administration Health Bureau, AAPHREML (Reference #- AAHB/4039/227) and also from Addis Ababa University, College of Natural and Computational Science IRB (IRB #- CNCSDO/604/13/2021), by Yekatit 12 Hospital Medical College (IRB protocol # 75/20) and also reviewed and

medRxiv preprint doi: https://doi.org/10.1101/2023.01.30.23285174; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

approved by the Federal Democratic Republic of Ethiopia National Ethics Committee at the Ministry of Science and Higher Education (MoSHE) (IRB #021/246/820/21).

Study Design, Period, and Setting

We leveraged samples collected from confirmed Ethiopian SARS-CoV-2 cases recorded between July 2020 and February 2022 to produce whole and near-whole genomes. Specifically, whole genome sequencing (WGS) was carried out on a subset of RT-PCR positive samples (N=353) collected during the first four waves of the pandemic in Ethiopia. The genomes can be further classified according to the sampling strategy, i.e., community surveillance (n=170), contacts of confirmed cases (n=78), and suspected cases (symptomatic but yet to be confirmed by laboratory results) (n=105), (Figure S2). Nasopharyngeal (NP) swab specimens were collected using 2ml of Viral Transport Medium (VTM), (China, Miraclean Technology Co., Ltd., www.mantacc.com) from patients in Addis Ababa, Amhara, Oromia, and the Southern Nations, Nationalities, and Peoples Regional States (provinces) of the country. The number of samples selected from each region was based on the epidemic distribution of the diseases across the country (Figure S3). These areas are known to have high population densities and cover almost three-quarters of the country's inhabitants [11, 12]. Only samples with cycle threshold (Ct) values under 30 were considered viable and submitted for sequencing

Quality Assurance

We implemented a comprehensive total quality management system to ensure the quality of our sequence data throughout the process (from pre-analytical to post-analytical). The specimens with RT-PCR Ct values <30 were stored in a −80°C freezer at Arsho Advance Medical Laboratories Plc: an ISO 15189 accredited laboratory [13].

RNA Extraction and Viral Detection

Extraction, purification, and viral detection using RT-PCR were done as per our previous work and respective manufacturer recommendations [14-17]. Viral detection was done at the Ethiopian Public Health Institute (EPHI), AAPHREM center laboratory, Yekatit 12 Hospital, Arsho medical laboratory, and Addis Ababa University.

medRxiv preprint doi: https://doi.org/10.1101/2023.01.30.23285174; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

These were amongst the established RT-PCR laboratories where the majority of COVID-19 testing was performed. SARS-CoV-2 positive samples from the first three waves of the pandemic were shipped to CERI/KRISP (South Africa), and from the fourth wave (103) to ILRI (Kenya) for whole genome sequencing. All biological specimens were transported following a triple packaging biosafety and biosecurity protocol.

Next-Generation Sequencing of SARS-CoV-2

WGS was performed using either the Illumina or the Oxford Nanopore Technology (ONT) sequencing platforms. Briefly, RNA was extracted on the automated Chemagic 360 system (Perkin Elmer) as per the manufacturer's instructions. Samples were lysed using proteinase K and bound using silica magnetic beads. Beads were then washed and the RNA was eluted and stored at -80 °C until use. SuperScript IV reverse transcriptase (Life Technologies) was then used, in combination with random hexamer primers, to convert extracted RNA to complementary DNA. Gene-specific multiplex PCR using the ARCTIC protocol was then performed. PCR was used to generate 400 base pair (bp) amplicons, with an overlap of 70 bp to cover the 30 kilobases (kb) SARS-CoV-2 genome. PCR products were purified using AmpureXP purification beads (Beckman Coulter, High Wycombe, UK), and quantification was performed using the Qubit double-strand DNA (dsDNA) High Sensitivity Assay Kit on a Qubit 4.0 instrument (Life Technologies). These libraries were then used for Illumina MiSeq and ONT GridION sequencing.

Illumina MiSeq indexed paired-end libraries were prepared using the Nextera DNA Flex Library Prep Kits (Illumina) as per the manufacturer's instructions. Tagmented amplicons were barcoded with a unique barcode using the Nextera CD Indexes (Illumina), which allows for library pooling. Prior to pooling, libraries were normalized to 4 nM and pooled, then denatured using sodium acetate. Pooled libraries were then diluted and spiked with 1 % PhiX Control v3 and sequenced using a 500-cycle v2 MiSeq Reagent Kit on the Illumina MiSeq instrument (Illumina, San Diego, CA, USA) [18. ONT Native Barcoding Expansion kits were used for ONT GridION sequencing according to the manufacturer's protocol. Samples were multiplexed on the FLO-

medRxiv preprint doi: https://doi.org/10.1101/2023.01.30.23285174; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

MIN106 flowcells and ran on the GridION X5. The MinKNOW software was used to monitor sequencing performance in real-time [19].

Metadata Management

Clinical and demographic metadata were collected from the confirmed cases using a structured assessment tool by trained healthcare professionals at the triage of the health facilities and from the community. A medical record number (MRN) was assigned to each patient as a unique anonymous identifier as their names were not linked to the MRNs submitted to sequence repositories such as GISAID, EPI_SET_221214bg doi: 10.55876/gis8.221214bg.

Sequence Alignment, Assembly, and Phylogenetic Analysis

Fastq sequences were assembled using Genome Detective 1.133 (http://www.genomedetective.com) [20] and the Coronavirus tool [21]. The initial assemblies obtained from Genome Detective were visualized and manually edited using Geneious Prime version 2022.2.2 [22,23] to remove low-quality mutations. Nextclade was used to determine the quality control profiles of the sequences. The quality metrics used for the sequences in this study included genome coverage greater than 80%, ensured the removal of unknown frameshifts, stop codon, and clustered mutations. Additionally, submissions with exceedingly high and missing data (N) <3000Ns) were excluded from downstream analyses. Nextclade was further employed to assign clades and lineage classifications to the sequences [24,25]. Sequences that met these quality control thresholds were deposited in the GISAID (https://www.gisaid.org/) database, EPI_SET_221214bg doi: 10.55876/gis8.221214bg].

To present a comprehensive analysis of the genomic epidemiology of SARS-CoV-2 in Ethiopia, the genomes generated in this study were combined with a globally representative set of genomes (n= 13589) that were sampled during the same period. All samples from the bordering countries to Ethiopia were included in the analysis to better model the relationship between Ethiopia and its Neighbors and infer cross-border transmission. This did not cause a sampling bias as these countries were

medRxiv preprint doi: https://doi.org/10.1101/2023.01.30.23285174; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

already characterized by a low number of sequences. Additionally, all global sequences belonging to the B.1.480 lineage which was predominant in Ethiopia and remained in circulation across the first three waves were included. Together, this resulted in a dataset of 13,942 genomes. Acknowledgment was given to the sequencing laboratories that contributed to the analysis set (EPI_SET_221214bg, DOI: 10.55876/gis8.221214bg).

Sequences were aligned using NextAlign [26] to obtain a good codon alignment of the sequences. A maximum likelihood tree topology was inferred from the resulting alignment in IQTREE 2 [27] using the General Time Reversible model of nucleotide substitution [28] The inferred phylogeny was used along with the associated metadata that was obtained from GISAID, to map discrete geographical locations to each of the tips and infer locations for the internal nodes. This was done using the Mugration package extension of TreeTime [29]. A custom Python script was then used to count the number of discrete changes occurring as we transcended the topology from the root towards the tips. In essence, this provided a crude estimate of the number and timing of viral exchanges (import-export) between Ethiopia and the rest of the world.

Data Analysis and Visualization

The data were analyzed and visualized using R version 4.2.0 using available packages and custom scripts. The tree was visualized using the R package ggtree version 3.0.4[30].

medRxiv preprint doi: https://doi.org/10.1101/2023.01.30.23285174; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Results

Socio-demographic Characteristics of the Study Participants along with SARS-CoV-2 Variants of Concerns (VOCs)

A total of 1300 nasopharyngeal swabs were collected from four provinces in the country. These samples included 181 (51.3%) specimens obtained from female patients while 172 (48.7%) were sampled from male patients. The patient ages ranged between 2 and 86 years old, although most of the cases were between 21- and 30-year-old patients, with an overall estimated median age of 31.45 (IQR=26-46) years. More than 77 % of the patients presented with mild cases (Table 1). Of these, we discarded 300 due to their high CT values (i.e., > 30). The remaining 1000 samples were subjected to the library preparation and 808 yielded sufficient RNA for WGS following RT-PCR amplification. The WGS resulted in 353 SARS-CoV-2 sequences that passed bioinformatics quality controls. (i.e., with genome coverage greater than 80%, a limited number of private mutations, no clustered mutations, and no misplaced stop codons). Figure S2 illustrates a detailed breakdown of the sample processing. During the study period, a combination of genetically distinct SARS-CoV-2 lineages were identified. The majority of these assemblies (91.7%) were classified as variants of concern (VOC).

Local Epidemic Dynamics

To illuminate the local epidemic dynamics in Ethiopia, we performed an in-depth study of the 353 high-quality SARS-CoV-2 genomes (Figure 1). The study period corresponds with the first four COVID-19 waves experienced in the country. The first wave occurred between August and September 2020, the second between February and March 2021, and the third occurred between July and October 2021. Each wave was characterized by higher rates of transmission and fatality than previous waves (Figure 1A). Notably, the third wave was more severe and lasted longer than the two previous waves. The fourth wave began with an uptick in cases in December 2021 and continued to February 2022. The wave was characterized by the highest rates of

medRxiv preprint doi: https://doi.org/10.1101/2023.01.30.23285174; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

community transmission yet observed (Figure 1A). However, compared to the global trend at the time, it resulted in fewer deaths.

Across the four waves, the peak number of new cases remained relatively consistent with the first and third waves reflecting a 7-day rolling average of approximately 1500 individuals. The second wave had a slightly higher 7-day rolling average of 2000 individuals whilst the fourth had the highest at over 4000 individuals (Figure 1A). The number of new deaths across each wave had a similar trend to the average number of new cases with the second and third waves having the highest number of new deaths at approximately 50 individuals per day (Figure 1B). Vaccine rollout commenced in April 2021 in Ethiopia and by February 2022, approximately 25% of the population had received at least one dose of Oxford-AstraZeneca or Sinopharm COVID-19 vaccines (Figure 1B).

Phylogenetic reconstruction and Variant Detection in Ethiopia

Ancestral state reconstruction showed that viral imports into Ethiopia occurred between August 2020 and January 2021, with the majority of importation events occurring in August 2020 [n=123], December 2020 [n=130], and January 2021 [n=169] (Figure 1C). In comparison, September and November 2020 corresponded with the highest numbers of inferred SARS-CoV-2 exports from Ethiopia (n=109 and n =137, respectively; Figure 1D, Figure S4). The majority of inferred importation events were from Eastern Africa [n=324] origins, whereas most of the inferred exportation events were generally attributed to Western European and Asian origins (n=20 and n=141 respectively). Overall, we identified 570 importation and 446 exportation events during the study period.

Our early sequences sampled between November and December 2020 represented two lineages, B.1/B.1.1 and B.1.480, with most of the sequences classified as B.1/B.1.1. These two lineages continued to circulate throughout the first quarter of 2021 (January to March). The B.1.480 lineage was thought to have originated in Ethiopia. In our study, 21 genome assemblies were assigned to this emerging lineage. (EPI_SET_230126dy, doi: 10.55876/gis8.230126dy). Phylogenetic inference

medRxiv preprint doi: https://doi.org/10.1101/2023.01.30.23285174; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

supported that this lineage was a monophyletic clade. Despite its persistence in Ethiopian populations for an extended period, this variant did not disseminate globally as was observed for other VOC and ultimately only constituted only 473 GISAID submissions during the progression of the pandemic, EPI_SET_230126vf, doi: 10.55876/gis8.230126vf. Nevertheless, according to GISAID submissions, this lineage was detected in neighboring countries such as Kenya, Somalia, Djibouti, and Guinea-Bissau. This lineage was further disseminated internationally where it was detected in Australia, the United States of America, Canada, Japan, Israel, Hong Kong, and South Korea. This period was followed by the detection and rise to dominance of VOCs in the country.

In January 2021, the first case of the Alpha variant was detected. Within a span of one month, it had reached equal prevalence to B.1/B.1.1. The B.1.1 continued to circulate in low prevalence with the cases detected until May 2021. Alpha was however short-lived as the Delta variant emerged. The Delta variant was first detected in February 2021. Thereafter, it quickly outcompeted all other lineages (Figure S5). By April, it had become the most prevalent variant. The predominant Delta variant sub lineages where AY.120 (116 sequences, 46.4%) and B.1.617.2 (50 sequences, 20%). The Delta variant seeded the 3rd wave in Ethiopia. Although no sequence data was available from September to December 2021, the majority of the cases sampled and sequenced from January 2022 were attributed to the Omicron lineage (Fig 1A & 2A). Over the course of the study period, we identified 37 distinct lineages in circulation (Fig 2 A, Fig 2B, Figure S6).

The phylogenetic reconstruction revealed close relatedness (not substantially observed levels of divergence) among sequences assigned to the same lineages. However, this observation did not hold for samples assigned to the Delta variant (Figure 2C). Sequences attributed to the Delta variant showed greater variation in sequence composition. Moreover, higher levels of phylogenetic clusters, associated with community transmission, were observed during the study period. Phylogenetic clusters and associated community transmission events were also observed for the Omicron lineage (Figure 2C).

medRxiv preprint doi: https://doi.org/10.1101/2023.01.30.23285174; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Discussion

In this study, we investigated the introduction of SARS-CoV-2 viral lineages, local transmission, and its evolution within Ethiopia. This study represents the first of its kind as no other molecular epidemiology investigation has been conducted for this country and provided an overview of the pandemic progression relative to a global context. Our results show that SARS-CoV-2 was introduced into Ethiopia on multiple occasions, with most introductions originating from Eastern African countries. These introductions included 37 distinct SARS-CoV-2 lineages and four VOCs, namely Alpha, Beta, Delta, and Omicron lineages. Of the introduced lineages the B1.480 persisted and remained in circulation from December 2020 to August of 2021.

Our findings show that as of February 2022, Ethiopia had experienced four distinct COVID-19 waves. Although various preventive strategies such as the mandatory wearing of masks, and media awareness campaigns were adopted together with a mandatory 14-day self-quarantine regulation for all international travelers arriving in the country [5], Ethiopia remained vulnerable to SARS-CoV-2 introductions. Our results showed that despite preventative measures viral introduction events continued to occur and were followed by community transmission. This in turn facilitated a continued increase in case numbers. This could be attributed to the partial restriction of public transport which is an import mode of SARS-CoV-2 transmission [5, 31]. During lockdowns, the operation of economic activities did not cease as they were deemed necessary to support the already fragile economic and socioeconomic situation of the country. This made lockdowns ineffective in preventing local transmission and epidemic growth. By 30 April 2021, the total number of cases and deaths had surpassed 257442 and 3688, respectively [1, 3], and has currently increased to >499000 and 7500 deaths.

Our findings show that Ethiopia experienced poor sampling mostly limited to Addis Ababa. Temporal sampling was also hampered by periods of limited sampling and, lack of local sequencing capacity resulting in substantial delays that in turn may cause

medRxiv preprint doi: https://doi.org/10.1101/2023.01.30.23285174; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

the degradation of samples during transit. Yet, an in-depth understanding of the COVID-19 pandemic progression in Ethiopia remains of paramount importance to aid the navigation of ongoing and future pandemics within these regions [32]. Indeed, Ethiopia has had several viral outbreaks in recent history, in addition to the ongoing COVID-19 pandemic. Some of the notable outbreaks include Measles, and mosquito-borne illnesses such as Yellow fever, Chikungunya, and Malaria [32, 33]. Thus, scaling up of local and regional pathogen genomic sequencing capacity and a robust pathogen genomic surveillance infrastructure is thus required to shorten the turnaround time and to allow for early public health response [34]. Additionally, during the onset of the pandemic, a survey on outbreak readiness highlighted a dire need for not only pathogen surveillance in Ethiopia but Ethiopia further scored only 52% on the Ready Score index, which shows that the nation still has progress to be made to increase case tracing and identification, increase healthcare and testing facilities, provide clear operational guidelines on preventive measures across various organizations, businesses, and community settings, as well as proactive steps to maintain life during social and economic lockdowns[3, 35]. Ethiopia, as with many other African countries, has limited resources to deal with these outbreaks, and often depends on international aid to help control and prevent these diseases [10, 36, 37].

Over the course of four waves, we estimated 570 introductions and 446 exportation events occurred. This is consistent with the relatively small number of lineages identified during the study period, although could also be attributed to under and sparse sampling that likely omitted lineages circulating at low prevalence. The short generation time associated with RNA viruses could also imply that viruses circulating during the period preceding the emergence of Omicron that became extinct would not have been detected. The phylogenetic inference and that of the geographical distribution of the Ethiopian-emerging B.1.480 lineage suggest that Ethiopia serves as a source for viral introductions not only to neighboring countries but also further abroad. Ethiopia serves as a travel hub for this African region connecting this region in Africa to neighboring countries and further abroad. Possible disease dissemination was most likely a result of travel to and from Ethiopia via air, land, and waterways [37, 38]. Ethiopia is strategically located on the Red Sea, making it an important transit

medRxiv preprint doi: https://doi.org/10.1101/2023.01.30.23285174; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

point for goods moving between Africa, the Middle East, and Asia. The main international airport in Ethiopia is Addis Ababa Bole International Airport facilitates high travel volumes which most likely contributed to viral amplification in the country followed by Ethiopian-originating viral exportation events. It is therefore imperative to have concerted, collaborative action to achieve pandemic mitigation.

We observed a reduction in the number of new deaths reported during the fourth wave. This is consistent with the immunity acquired protection from a large number of infections from the preceding waves and increases in the total number of vaccinated individuals. A seroprevalence study among health care workers revealed a seropositivity rate of 39.6% [39] while another study the estimated the prevalence rate at over 50% [40]. However, only about 0.4% of the population has reportedly been infected with COVID-19: much fewer than the estimated seroprevalence rates estimated for the population. Therefore, taken together these statistics suggest that case numbers may remain widely underreported. Reduced testing further hinders effective genome surveillance as fewer samples were available to be subjected to whole genome analyses and influences the accuracy of epidemiological conclusions drawn.

In comparison to other countries, Ethiopia has very low vaccination coverage. As of December 2021, at least 1 000 000 Ethiopians had been vaccinated. It is important to note that COVID-19 vaccines in Ethiopia were prioritized based on criteria such as occupation, age, medical condition, people that work in aggregate settings, the elderly, and people with comorbidities known to increase the risk of adverse COVID-19 outcomes[41]. Moreover, priority was given to those deemed as frontline medical staff, followed by non-frontline medical staff. This strategy was effective in slowing the evolutionary rate of the virus as SARS-CoV-2 is prone to evolution in immunosuppressed individuals experiencing chronic infection [42-44]. Vaccination has also been shown to decrease the overall SARS-CoV-2 infection rate from 9.0% (95% CrI: 8.4% – 9.4%) without vaccination to 4.6% (95% CrI: 4.3% – 5.0%) with the highest relative reduction noted among individuals aged 65 and above. Adverse

medRxiv preprint doi: https://doi.org/10.1101/2023.01.30.23285174; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

outcomes, such as deaths, are reduced by approximately 69.3% (95% CrI: 65.5%-73.1%) with lowered vaccination coverage [45].

Analysis of genomes and lineages across the study period highlighted the changes in the population dynamics of the viral lineages circulating in Ethiopia. The B.1 and B.1.1 lineages dominated the first wave, persisted throughout the next two waves, and were characterized by the well-known D614G mutation [46]. This mutation has been linked to increased viral replication and transmissibility [38, 46]. Subsequent waves were dominated by the VOCs Alpha, Beta, Delta, and Omicron. These VOCs evolved to evade overcome host immunity from infection with ancestral viruses and vaccination. By doing so these newly emerging variants fueled renewed infectious waves and were often associated with increased transmissibility compared to their genetic predecessors [47-49]. The Omicron variant (specifically, lineage BA.1.1) had a reproduction number four times higher than Delta. It is considered the fifth variant of concern first detected in November/December 2021 [50-53].

One important lineage in the context of Ethiopia was the B.1.480, a distinct B lineage, which emerged during the second wave. This variant was responsible for 2.77% of the sampled cases. Notably, this variant was previously detected in passengers originating from not only Ethiopia but also with those originating from European countries such as the United Kingdom and France, as well as from travelers from United Arab Emeritus [50-53]). Unlike other VOCs, this lineage did not reach global transmission and has only 473 submissions to the GISAID platform, however, it did persist in Ethiopian populations for extended periods of time. Other worrisome mutations carried by this lineage included the Spike mutation M1229I and D614G [46,47,49,54].

In conclusion, the changing nature of the pandemic over time in Ethiopia has been driven by lineage turnovers that, while dominated by VOCs and B.1.480, include other lineages (A, B.1, B.1.1). Results from this study, and that of others (ref listed above), showed that despite pandemic mitigation strategies implemented by the country, Ethiopia remained vulnerable to viral introduction events and served as a source of

medRxiv preprint doi: https://doi.org/10.1101/2023.01.30.23285174; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

viral introductions internationally. The COVID-19 pandemic is still ongoing and the evolution of the virus is continuing to yield new variants some of which will likely reflect altered viral behavior such as increased transmissibility, immune evasiveness, or altered pathogenicity. It is therefore crucial that ongoing genomic surveillance be strengthened and conducted to present real-time data generation to determine the geographic distribution of these variants and enable the implementation of appropriate disease mitigation strategies.

medRxiv preprint doi: https://doi.org/10.1101/2023.01.30.23285174; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Acronyms /abbreviations

AAPHREML	Addis Ababa public health research and emergency management laboratory
AAU	Addis Ababa University
ACDC	Africa center for disease prevention and control
CERI	Centre for Epidemic Response and Innovation
CI	Confidence Interval
CT	Cycle Threshold
GISAID	Global Initiative on Sharing All Influenza Data
KRISP	KwaZulu-Natal Research Innovation and Sequencing Platform
NAAT	Nucleic Acid Amplification Tests
PCR	Polymerase Chain Reaction
RNA	Ribose Nucleic Acid
RT-PCR	Reverse Transcriptase Polymerase Chain Reaction
SARS-CoV-2	severe acute respiratory syndrome novel corona virus-2
VOCs	Variants of Concern
VTM	Virus Transport Medium
WHO	World Health Organization
SDG	sustainable development goal
COVID-19	Coronavirus disease 2019

Funding

This research was financed by Addis Ababa University through the COVID-19-AAU research fund for staff with a reference #- PR/5.15/590/12/20 and adaptive research and problem-solving projects with Ref # AR/043/2021 and RD/PY-148/2021. Also, this work was realized by the generous financial and technical support of the AU through Africa CDC, PGI. No more external funding was received. The APC was funded by Africa Pathogen Genomics Initiative (Africa PGI).

The funders had no role in the study design, data collection, analysis, decision to publish, or preparation of the manuscript. The contents are purely the responsibilities of the authors and did not represent and reflect the view of the founder.

Author Contributions

AS and AFD conceived and designed the experiments; AS, DT and SEJ performed the data analysis and experiments; AS, DT, AFD and SEJ analyzed the data; GM, SO,

medRxiv preprint doi: https://doi.org/10.1101/2023.01.30.23285174; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

SKT, CB, DM, RL, HT, MM, SvW, EW, TDO contributed materials/analysis tools; AT, AFD and SEM supervise the work; AS, DT, SvW and SEJ wrote the paper. All authors read the final version of the manuscript.

Informed Consent Statement

All participants gave written informed consent for participation and publication.

Declaration of Competing Interest

We all the authors declare that we have no known competing interests or personal relationships that could have appeared to influence the work reported in this research paper.

Data availability

All the generated sequences used for this manuscript have been deposited in the GISAID sequence database and are purely publicly available. However, it's subject to the terms and conditions of the GISAID database, https://www.gisaid.org/, GISAID Identifier: EPI_SET_221214bg, DOI: 10.55876/gis8.221214bg.

Acknowledgment

We would like to acknowledge Addis Ababa University for giving us the opportunity and financing the research. This work is realized with the generous financial and technical support of Africa CDC, PGI

We are very grateful and acknowledge the CERI and KRISP (South Africa) & ILRI (Kenya) for supporting this work by performing the whole genomic sequencing.

We also wish to extend our gratitude to Arsho Medical Laboratories for supporting this research by giving us a -80 ^{Oc} refrigerator for centrally storing our specimens.

Last but not least we are very glad and thankful to Retina Pharmaceutical for supporting this work by availing required pharmaceutical inquiries.

medRxiv preprint doi: https://doi.org/10.1101/2023.01.30.23285174; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Reference

1. Ethiopia: the World Bank.https://www.worldbank.org/en/country/ethiopia/overview . Accessed on 25 Jan 2023.
2. Ebssa Wakwaya. "The promise of regional projects for Africaâ€™s landlocked countries: Focusing on Ethiopia." African Journal of Political Science and International Relations 9.2 (2015): 67-75
3. Zhang W, Persoz L, Hakiza S, Biru L, Girmatsion L. Impact of COVID-19 on Food Security in Ethiopia. *Epidemiologia*. 2022; 3(2):161-178. https://doi.org/10.3390/epidemiologia3020013
4. https://www.un.org/ohrlls/sites/www.un.org.ohrlls/files/impact_of_covid19_and_responses_in_lldcs.pdf
5. University JH. Johns Hopkins University JH. worldometers COVID-19 Daily update 2022 [Available from: https://www.worldometers.info/coronavirus/.
6. World Health Organization (WHO Africa). First case of COVID-19 confirmed in Ethiopia. https://www.afro.who.int/news/first-case-covid-19-confirmed-ethiopia#:~:text=March%2013%2C%202020%2C%20The%20Federal,in%20China%20in%20December%202019.
7. Lanyero B, Edea ZA, Musa EO, Watare SH, Mandalia ML, Livinus MC, et al. Readiness and early response to COVID-19: achievements, challenges, and lessons learnt in Ethiopia. BMJ global health. 2021; 6(6).
8. Ethiopian Public Health Institute, EPHI. COVID-19 PANDEMIC PREPAREDNESS AND RESPONSE IN ETHIOPIA WEEKLY BULLETIN Nov 2021 [updated 2022. Available from: https://ephi.gov.et/download/pheoc/.
9. WHO. COVID-19 Preparedness Bulletin Ethiopia 2020 [Available from: https://extranet.who.int/sph/covid-19-preparedness-bulletin-ethiopia.
10. Amhare AF, Tao Y, Li R, Zhang L. Early and Subsequent Epidemic Characteristics of COVID-19 and Their Impact on the Epidemic Size in

medRxiv preprint doi: https://doi.org/10.1101/2023.01.30.23285174; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Ethiopia. *Front Public Health*. 2022;10: 834592. Published 2022 May 11. doi:10.3389/fpubh.2022.834592

11. Leulseged TW, Abebe KG, Hassen IS, et al. COVID-19 disease severity and associated factors among Ethiopian patients: A study of the millennium COVID-19 care center. *PLoS One*. 2022;17(1):e0262896. Published 2022 Jan 27. doi:10.1371/journal.pone.0262896
12. Abdella S, Riou S, Tessema M, et al. Prevalence of SARS-CoV-2 in urban and rural Ethiopia: Randomized household serosurveys reveal level of spread during the first wave of the pandemic. *EClinicalMedicine*. 2021; 35:100880. Published 2021 May 7. doi:10.1016/j.eclinm.2021.100880
13. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic acids research. 2004;32(5):1792-7.
14. Sisay A, Abera A, Dufera B, Endrias T, Tasew G, Tesfaye A, et al. Diagnostic accuracy of three commercially available one step RT-PCR assays for the detection of SARS-CoV-2 in resource limited settings. PloS one. 2022; 17(1):e0262178.
15. MOLBIOL T. RT-PCR test kits and VirSNiP Mutation Assays for strain surveillance [Available from: https://www.tib-molbiol.de/covid-19.
16. World Health Organization W. Emergency Use Listing Procedure for in vitro diagnostics 2020 [Available from: https://www.who.int/teams/regulation-prequalification/eul/in-vitro-emergency-use-listing-procedure.
17. BGI. Real-Time Fluorescent RT-PCR Kit for Detecting SARS-CoV-2 2020 [Available from: https://www.bgi.com/us/sars-cov-2-real-time-fluorescent-rt-pcr-kit-ivd/
18. Tshiabuila D, Giandhari J, Pillay S, et al. Comparison of SARS-CoV-2 sequencing using the ONT GridION and the Illumina MiSeq. *BMC Genomics*. 2022; 23(1):319. Published 2022 Apr 22. doi:10.1186/s12864-022-08541-5
19. Pembaur A, Sallard E, Weil PP, Ortelt J, Ahmad-Nejad P, Postberg J. Simplified Point-of-Care Full SARS-CoV-2 Genome Sequencing Using Nanopore Technology. Microorganisms. 2021; 9(12).

medRxiv preprint doi: https://doi.org/10.1101/2023.01.30.23285174; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

20. Vilsker M, Moosa Y, Nooij S, et al. Genome Detective: an automated system for virus identification from high-throughput sequencing data. *Bioinformatics*. 2019;35(5):871-873. doi:10.1093/bioinformatics/bty695
21. Cleemput S, Dumon W, Fonseca V, et al. Genome Detective Coronavirus Typing Tool for rapid identification and characterization of novel coronavirus genomes. *Bioinformatics*. 2020;36(11):3552-3555. doi:10.1093/bioinformatics/btaa145
22. Larsson A. AliView: a fast and lightweight alignment viewer and editor for large datasets. Bioinformatics (Oxford, England). 2014; 30(22):3276-8.
23. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic acids research. 2004; 32(5):1792-7.
24. Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data - from vision to reality. Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2017;22(13).
25. Nextclade. Next clade. https://clades.nextstrain.org/ 2021 [Available from: https://clades.nextstrain.org/.
26. Aksamentov I., Neher R. Nextalign: Viral Genome Reference Alignment. [(accessed on 16 Jan 2023]. Available online: https://github.com/neherlab/nextalign
27. Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von Haeseler A, Lanfear R. IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era. Mol Biol Evol. 2020 May 1;37(5):1530-1534. doi: 10.1093/molbev/msaa015.
28. Gatto L, Catanzaro D, Milinkovitch MC. Assessing the applicability of the GTR nucleotide substitution model through simulations. *Evol Bioinform Online*. 2007;2:145-155. Published 2007 Feb 4.
29. Pavel Sagulenko, Vadim Puller, Richard A Neher, TreeTime: Maximum-likelihood phylodynamic analysis, *Virus Evolution*, Volume 4, Issue 1, January 2018, vex042, https://doi.org/10.1093/ve/vex042

medRxiv preprint doi: https://doi.org/10.1101/2023.01.30.23285174; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

30. Yu G, Smith DK, Zhu H, Guan Y, Lam TT-Y. ggtree: an r package for visualization and annotation of phylogenetic trees with their covariates and other associated data. Methods in Ecology and Evolution. 2017;8(1):28-36.

31. Ellingjord-Dale, M., Kalleberg, K.T., Istre, M.S. *et al.* The use of public transport and contraction of SARS-CoV-2 in a large prospective cohort in Norway. *BMC Infect Dis* 22, 252 (2022). https://doi.org/10.1186/s12879-022-07233-5

32. Mekuriaw W, Kinde S, Kindu B, Mulualem Y, Hailu G, Gebresilassie A, et.,al. Epidemiological, Entomological, and Climatological Investigation of the 2019 Dengue Fever Outbreak in Gewane District, Afar Region, North-East Ethiopia. *Insects*. 2022; 13(11):1066. https://doi.org/10.3390/insects13111066

33. Mengesha Tsegaye, M., Beyene, B., Ayele, W. *et al.* Sero-prevalence of yellow fever and related Flavi viruses in Ethiopia: a public health perspective. *BMC Public Health* **18**, 1011 (2018). https://doi.org/10.1186/s12889-018-5726-9

34. Tegally H, San JE, Cotten M, et al. The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance. *Science*. 2022;378(6615):eabq5358. doi:10.1126/science.abq5358

35. Abagero A, Ragazzoni L, Hubloue I, Barone-Adesi F, Lamine H, Addissie A, Della Corte F, Valente M. A Review of COVID-19 Response Challenges in Ethiopia. *Int. J. Environ. Res. Public Health.* 2022; 19(17):11070. https://doi.org/10.3390/ijerph191711070

36. Tessema GA, Kinfu Y, Dachew BA, Tesema AG, Assefa Y, Alene KA, et al. The COVID-19 pandemic and healthcare systems in Africa: a scoping review of preparedness, impact and response. BMJ global health. 2021;6(12):e007179.

37. Nigussie H. The Coronavirus Intervention in Ethiopia and the Challenges for Implementation. Front. Commun., 21 May 2021 Sec. Health Communication Volume 6 – 2021. https://doi.org/10.3389/fcomm.2021.562512

38. Ngeh S, Vogt F, Sikazwe CT, et al. Travel-associated SARS-CoV-2 transmission documented with whole genome sequencing following a long-haul international flight. *J Travel Med*. 2022;29(6):taac057. doi:10.1093/jtm/taac057

medRxiv preprint doi: https://doi.org/10.1101/2023.01.30.23285174; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

39. Gelanew T, Seyoum B, Mulu A, et al. High seroprevalence of anti-SARS-CoV-2 antibodies among Ethiopian healthcare workers. *BMC Infect Dis*. 2022;22(1):261. Published 2022 Mar 16. doi:10.1186/s12879-022-07247-z
40. Gudina EK, Ali S, Girma E, et al. Seroepidemiology and model-based prediction of SARS-CoV-2 in Ethiopia: longitudinal cohort study among front-line hospital workers and communities. *Lancet Glob Health*. 2021;9(11):e1517-e1527. doi:10.1016/S2214-109X(21)00386-7
41. COVID-19 Vaccine tracker. https://www.reuters.com/graphics/world-coronavirus-tracker-and-maps/vaccination-rollout-and-access/
42. Kemp, S.A., Collier, D.A., Datir, R.P. *et al.* SARS-CoV-2 evolution during treatment of chronic infection. *Nature* 592, 277–282 (2021). https://doi.org/10.1038/s41586-021-03291-y
43. Wilkinson SAJ, Richter A, Casey A, Osman H, Mirza JD, Stockton J, et al. Recurrent SARS-CoV-2 mutations in immunodeficient patients. Virus evolution. 2022;8(2):veac050.
44. Weigang, S., Fuchs, J., Zimmer, G. *et al.* Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants. *Nat Commun* 12, 6405 (2021). https://doi.org/10.1038/s41467-021-26602-3
45. Moghadas SM, Vilches TN, Zhang K, et al. The impact of vaccination on COVID-19 outbreaks in the United States. Preprint. *medRxiv*. 2021;2020.11.27.20240051. Published 2021 Jan 2. doi:10.1101/2020.11.27.20240051
46. Korber B, Fischer WM, Gnanakaran S, et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. *Cell*. 2020;182(4):812-827.e19. doi:10.1016/j.cell.2020.06.043
47. Harvey, W.T., Carabelli, A.M., Jackson, B. *et al.* SARS-CoV-2 variants, spike mutations and immune escape. *Nat Rev Microbiol* 19, 409–424 (2021). https://doi.org/10.1038/s41579-021-00573-0
48. Liu Y, Rocklöv J. The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus. J Travel Med. 2021

medRxiv preprint doi: https://doi.org/10.1101/2023.01.30.23285174; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Oct 11;28(7):taab124. doi: 10.1093/jtm/taab124. PMID: 34369565; PMCID: PMC8436367.

49. Thakur S, Sasi S, Pillai SG, et al. SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines. *Front Med (Lausanne)*. 2022;9: 815389. Published 2022 Feb 22. doi:10.3389/fmed.2022.815389
50. Shrivastava S, Mhaske ST, Modak MS, Virkar RG, Pisal SS, Mishra AC, et al. Emergence of two distinct variants of SARS-CoV-2 and an explosive second wave of COVID-19: the experience of a tertiary care hospital in Pune, India. Archives of virology. 2022; 167(2):393-403.
51. Dhama K, Nainu F, Frediansyah A, Yatoo MI, Mohapatra RK, Chakraborty S, et al. Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies. Journal of Infection and Public Health. 2023; 16(1):4-14.
52. Zhou Y, Zhi H, Teng Y. The outbreak of SARS-CoV-2 Omicron lineages, immune escape, and vaccine effectivity. *J Med Virol*. 2022;10.1002/jmv.28138. doi:10.1002/jmv.28138
53. Corriero A, Ribezzi M, Mele F, Angrisani C, Romaniello F, Daleno A, et., al. COVID-19 Variants in Critically Ill Patients: A Comparison of the Delta and Omicron Variant Profiles. *Infectious Disease Reports*. 2022; 14(3):492-500. https://doi.org/10.3390/idr14030052
54. Dubey, A., Choudhary, S., Kumar, P. *et al.* Emerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications. *Curr Microbiol* **79**, 20 (2022). https://doi.org/10.1007/s00284-021-02724-1

medRxiv preprint doi: https://doi.org/10.1101/2023.01.30.23285174; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Tables, Figures and Supplementary Files

Table 1. Socio-demographic characteristics of study participants along with VOC of SARS-CoV-2 in Ethiopia, 2020-2022.

Variable	Class	Frequency (%)	Variant (VOC)			
			Alpha	Beta	Delta	Omicron
Sex	Female	181 (51.3)	10	2	99	57
	Male	172 (48.7)	7	1	102	46
Age Range (years)	1-20	40 (11.3)	7	1	19	8
	21-30	121 (34.3)	1	1	80	25
	31-40	84 (23.8)	5	1	43	30
	41-50	41 (11.6)	2	0	25	12
	51-60	21 (10.2)	2	0	18	15
	>60	31 (8.8)	0	0	16	13
Reason for testing (during sampling)	Suspect	107 (30.3)	6	1	133	2
	Contacts of confirmed cases	79 (22.4)	8	2	45	1
	Community Surveillance	167 (47.3)	3	0	23	100
Clinical Status of the clients while sampling	Asymptomatic*	53 (15)	3	0	37	5
	Mild	273 (77.3)	14	3	142	94
	Sever	27 (7.7)	0	0	22	4

*Asymptomatic – a person has tested positive for COVID-19 but never exhibits any signs or symptoms of the disease

Figure 1: SARS-CoV-2 epidemiology and variant turnover in Ethiopia: (a) 7-day rolling average for the number of new SARS-CoV-2 cases. Others, represented in blue, comprise mostly B lineages including B, B.1, and B.1.1 lineages. The size of the dot is indicative of the variant proportion in the population. (b) The proportion of individuals that have received at least one vaccine dose in Ethiopia compared to the number of new deaths that occurred. (c) Summary of the mean number of detected introductions into Ethiopia binned by month for different regions across the dataset. (d) Summary of the mean number of detected exportations out of Ethiopia to different regions binned by month.

Figure 2: SARS-CoV-2 lineage diversity in Ethiopia. (A) Proportions of SARS-CoV-2 lineages, classified by Pangolin nomenclature, circulating between June 2020 and February 2022 in Ethiopia. (B) Absolute counts of SARS-CoV-2 genomes throughout the study period. Only VOCs and major lineages are listed in the legend. (C) Maximum-Likelihood phylogeny of 353 SARS-CoV-2 genomes. Branches are colored by lineage.

medRxiv preprint doi: https://doi.org/10.1101/2023.01.30.23285174; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

List of Supplementary Files

Table S1- Timeline of COVID-19 and major events following the first confirmed cases in Ethiopia

Figure S2- Consortium Diagram of Sampling for Molecular Epidemiology and Diversity of SARS-CoV-2 in Ethiopia

Figure S3- The sampling area covers in Ethiopia

Figure S4-Major SARS-CoV-2 lineages of detected imported and exported Ethiopia between June 2020 and February 2022

Figure S5- SARS-CoV-2 Delta VOC sub tree molecular clock, Ethiopia.

medRxiv preprint doi: https://doi.org/10.1101/2023.01.30.23285174; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Figure S6-Major SARS-CoV-2 lineages identified Ethiopia between June 2020 and February 2022

medRxiv preprint doi: https://doi.org/10.1101/2023.01.30.23285174; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Table S1 Summary of the COVID-19 timeline and major events following the first confirmed cases in Ethiopia

Timeline	Major events	Remark
December 2019/January 2020	Wuhan City, Hubei Province, China, which was reported to the WHO on 31 December 2019. Wuhan, China, was reported in January 2020	
27 January 2020	Prior to the WHO's declaration of a global pandemic, the federal democratic republic of Ethiopia Council of Ministers 'activated' a National Public Health Emergency Preparedness Centre, EOC and began preparations to deal with a potential outbreak of Covid-19	
30 January 2020	the Director-General of the WHO declared COVID-19 a Public Health Emergency of International Concern	
7 February 2020	Ethiopia set up the national Influenza and Arboviruses reference laboratory as the first COVID-19 testing laboratory in the country with the support from WHO and ACDC.	
March 11, 2020-	WHO declared COVID-19 as a Pandemic	
March 13, 2020, ***	On 12 March 2020, a week after entering the country from Burkina Faso, a 48-year-old Japanese national presented **himself** at a public health center in the capital city, Addis Ababa, and was diagnosed as having COVID-19. Since Ethiopia did not have the capacity to test for COVID-19 at the onset. Thus, samples were initially transported for testing to the National Institute for Communicable Diseases (NICD) Laboratory in South Africa	
15 March 2020	The second confirmed case from Ethiopian nationalities (three additional)cases of the COVID-19 were reported	
20 March 2020	Anyone entering the country/international travelers/ should stay in quarantine for up to 14 days at their costs	
23 March 2020	Ethiopia closed all land borders and deployed security forces to halt the movement of people along the borders (National lockdown….)	
24 March 2020	• banned all public gatherings and sports events • The closure of bars and clubs • all federal employees were to work from home, except those designated by each ministry and federal agency as essential workers	
05 April 2020	The First COVID-19-related confirmed death	
8 April 2020	A state of emergency was declared giving authorities across-the-board powers to battle the disease	
06 March 2021 **after a year of pathogen occurrence*	The first genome sequence of SARS-CoV-2 sampled from Ethiopia was submitted to the GISAID database	
13March, 2021	First vaccination started	

*** Form 13 March-Mid April 2020-Sample were tested by referral to NICD, the country had no RT-PCR testing center during this time

medRxiv preprint doi: https://doi.org/10.1101/2023.01.30.23285174; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Figure S2--Consortium Diagram of Sampling for Molecular Epidemiology and Diversity of SARS-CoV-2 in Ethiopia



*because of old specimen, long shipping time, backlog seq., temp not maintained ...

medRxiv preprint doi: https://doi.org/10.1101/2023.01.30.23285174; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Figure - S3a- Sampling area for Molecular Epidemiology and Diversity of SARS-CoV-2 in Ethiopia



Table S3b: Sequence proportion of the regional government

Name of Regional	Proportion of sequencing (%)
Addis Ababa	80%
Oromia	8%
Amhara	5%
SNNPR and Sidama	5%
Others	2%

medRxiv preprint doi: https://doi.org/10.1101/2023.01.30.23285174; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .



Figure S 4-Major SARS-CoV-2 lineages *of detected imported and exported Ethiopia between June 2020 and February 2022*

medRxiv preprint doi: https://doi.org/10.1101/2023.01.30.23285174; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .



Figure S 5 - SARS-CoV-2 Delta VOC sub tree molecular clock, Ethiopia.

medRxiv preprint doi: https://doi.org/10.1101/2023.01.30.23285174; this version posted January 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .



Figure S 5-Major SARS-CoV-2 lineages circulating in Ethiopia between June 2020 and February 2022









Figure 1: SARS-CoV-2 epidemiology and variant turnover in Ethiopia: (a) 7-day rolling average for the number of new SARS-CoV-2 cases.Size of the dot is indicative of the variant proportion in the population. (b) The proportion of individuals that have received at least one vaccine dose in Ethiopia compared to the number of new deaths that occurred. (c) Summary of the mean number of detected introductions into Ethiopia binned by month (d) Summary of the mean number of detected exportations out of Ethiopia to different regions binned by month.



Figure 2: SARS-CoV-2 lineage diversity in Ethiopia.
(A) Proportions of SARS-CoV-2 lineages, classified by Pangolin nomenclature, circulating between June 2020 and February 2022 in Ethiopia.
(B) Absolute counts of SARS-CoV-2 genomes throughout the study period. Only VOCs and major lineages are listed in the legend.
(C) Maximum-Likelihood phylogeny of 353 SARS-CoV-2 genomes. Branches are colored by lineage.